Cantor Fitzgerald Reaffirms Overweight Rating for Astria Therapeutics (NASDAQ:ATXS)

Key Points

• Astria Therapeutics (NASDAQ:ATXS) has received an "overweight" rating from Cantor Fitzgerald, with a price target of $49.00.
• Several analysts have given positive ratings, with a consensus price target of $29.40 and a majority rating of "Buy."
• The company reported earnings of ($0.57) per share, which surpassed expectations of ($0.61) by $0.04 during its last quarterly report.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report)'s stock had its "overweight" rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $49.00 price objective on the biotechnology company's stock.

Several other research firms have also weighed in on ATXS. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Finally, JMP Securities lifted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $30.20.

Astria Therapeutics Trading Down 5.7%

Shares of ATXS traded down $0.43 on Wednesday, reaching $7.05. 1,303,719 shares of the company's stock were exchanged, compared to its average volume of 348,468. The business has a 50 day moving average price of $6.77 and a two-hundred day moving average price of $5.76. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92. The stock has a market capitalization of $397.90 million, a P/E ratio of -3.51 and a beta of 0.42.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04. Equities research analysts predict that Astria Therapeutics will post -1.65 EPS for the current year.

Hedge Funds Weigh In On Astria Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATXS. JPMorgan Chase & Co. raised its stake in shares of Astria Therapeutics by 4,607.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company's stock valued at $9,091,000 after purchasing an additional 1,660,039 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Astria Therapeutics by 605.3% in the first quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after purchasing an additional 550,706 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Astria Therapeutics by 59.7% in the second quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company's stock valued at $5,733,000 after purchasing an additional 400,000 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Astria Therapeutics by 8.2% in the second quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock valued at $24,238,000 after purchasing an additional 342,000 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Astria Therapeutics in the second quarter valued at about $1,608,000. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.